At COO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based COO’ operating in the Pharmaceutical space. If you think a COO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Jason Rickard
Chief Operating Officer of Ironwood Pharmaceuticals
Jason Rickard is the Chief Operating Officer at Ironwood Pharmaceuticals.
Follow Jason Rickard:
About Ironwood Pharmaceuticals: Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Don Calabria
COO of Endonovo Therapeutics
Don Calabria Chief Operating Officer brings over seventeen years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance, and business development. Mr. Calabria has a deep level of experience in analyzing companies, determining the operational efficiencies, and conducting operational due diligence on targeted acquisitions. Previously, Mr. Calabria served as President of Gemini Consulting Group, Inc., a boutique consulting firm which specialized in providing consulting services to companies in multiple marker segments with a core focus directed towards capital structuring and investments, brand strategy and marketing, M&A activities, and operational efficiencies. Prior to this, Mr. Calabria was the VP of Operations for TrinTel Communications; the largest privately held Infrastructure Company in the wireless telecommunications industry. As part of the Company’s initial Senior Management team, which grew the company to a $350+ million valuation in under three years, Mr. Calabria specialized in managing joint venture agreements and strategic alliances as well as directing all subsidiary operations including regional sales, marketing, and business development practices. Prior to this, as the Director of Operations for Wireless Solutions, LLC, he helped facilitate the sale of the company to TrinTel Communications. Mr. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a BS in Management from Arizona State University.
Follow Don Calabria:
About Endonovo Therapeutics: Endonovo Therapeutics is a biotechnology company developing off-the-shelf regenerative products.
Steven Ertel
Chief Operating Officer of Acceleron Pharma
Mr. Ertel joined Acceleron in January 2006 as a Chief Operating Officer. Mr. Ertel established Acceleron’s business development function and currently leads business development, commercial strategy and program management functions. Mr. Ertel has over 20 years of experience in the biotechnology industry at Vivus, Inc., Genentech, Inc., Biogen Idec, Inc., and Synta. His responsibilities at these companies included program management for preclinical and clinical stage programs, commercial strategy for clinical stage programs, market launch of a novel biologic agent, and business development. Mr. Ertel began his career in the venture capital industry at Oxford Bioscience Partners. Mr. Ertel received a BSE in biomedical engineering from Duke University and an MBA from the Wharton School at the University of Pennsylvania.
Follow Steven Ertel:
About Acceleron Pharma: Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
Jason Cole
Chief Operating and Legal Officer of Bluebird Bio
Follow Jason Cole:
About Bluebird Bio: Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Jeff Yordon
President & COO of Athenex
Jeffrey Yordon has held multiple senior management positions in the pharmaceutical industry over the last 46 years. Mr. Yordon was the Founder, Chairman and CEO of Sagent Pharmaceuticals which had a market cap of $1.6 billion when he left the company in 2015. Previous to that, Mr. Yordon was the COO of American Pharmaceutical Partners where he was a founder and the company was eventually sold to Fresenius for $5.5 billion. Mr. Yordon was the CEO of Faulding Pharmaceuticals, CEO and Founder of YorPharm, COO of Gensia Pharmaceuticals and he was instrumental in the sale of all of these companies to Apotex, Teva and Hospira for prices upwards of $3.5 billion. Mr. Yordon has successfully taken four companies public and all of the companies sold for significant returns for his shareholders. Mr. Yordon was an Ernst & Young Entrepreneur of the Year in 2011, was inducted into the Chicago Entrepreneur Hall of Fame in 2014, won a prestigious Innovation Award from the City of Chicago, was appointed to the Chicago Innovation Council in 2014, was appointed by Governor Rauner to the Illinois Sports Facilities Authority in 2015, has been appointed to be the Chairman of the Board of the Northern Illinois University Foundation, is the Chair of the NIU Political Science Advisory Panel and is actively involved in the NIU Athletic program. Mr. Yordon has three children and presides in the Chicago area.
Follow Jeff Yordon:
About Athenex, Sagent Pharmaceuticals: Athenex focuses on the development and commercialization of therapies for cancer and immunomodulatory diseases.
Bruce Given
Chief Operating Officer of Arrowhead Pharmaceuticals
Follow Bruce Given:
About Arrowhead Pharmaceuticals: Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Pamela Hudson
Chief Operating Officer & Center for Digital Health Innovation of University of California, San Francisco
Pamela Hudson is the Chief Operating Officer & Center for Digital Health Innovation at UCSF.
Follow Pamela Hudson:
About BayHealth Development, Gordon and Betty Moore Foundation, UCSF health, University of California, San Francisco, University of California, San Francisco: Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine
Anish Bhatnagar
Chief Executive Officer, President & Chief Operating Officer of Soleno Therapeutics
Dr. Bhatnagar was appointed as our Chief Executive Officer in February 2014. Prior to that, he served as our President and Chief Operating Officer. Dr. Bhatnagar joined us in 2006, and has held positions of increasing responsibility since then. Dr. Bhatnagar is a physician with over 15 years of experience in the medical device and biopharmaceutical industries. His experience spans development of biologics, drugs, drug-device combinations and diagnostic as well as therapeutic medical devices. His prior experience includes working at Coulter Pharmaceuticals, Inc. from 1998 to 2000 and Titan Pharmaceuticals, Inc. from 2000 to 2006. He is the author of several peer-reviewed publications, abstracts and book chapters. He obtained his medical degree at SMS Medical College in Jaipur, India and completed his Residency and Fellowship training in the U.S. at various institutions, including Georgetown University Hospital and the University of Pennsylvania.
Follow Anish Bhatnagar:
About Soleno Therapeutics: Soleno Therapeutics is a clinical-stage biopharmaceutical company
George Hillman
COO, VP & Co-Founder of Viracta Therapeutics
George Hillman is the Co-Founder, Chief Operating Officer, and Vice President of Viracta Therapeutics.
Follow George Hillman:
About Viracta Therapeutics: Viracta Therapeutics is a precision oncology company focused on new treatment of virus-associated malignancies.
Mattan Griffel
Co-Founder/President & COO of Ophelia
Mattan is an award-winning faculty member at Columbia Business School and a two-time Y Combinator-backed entrepreneur. He co-founded Ophelia, a company that helps people quit opioids without having to go to rehab. Mattan is also an Innovation Fellow at the Lang Center for Entrepreneurship and was selected as one of Forbes’ 30 Under 30 in Education.
Follow Mattan Griffel:
About One Month | Learn to Code in 30 Days, Ophelia, Sandbox Network: Ophelia offers medication and support for quitting opioids.
Suresh Jain
Co-Founder, President & COO of Acylin Therapeutics
Follow Suresh Jain:
About Acylin Therapeutics: Acylin Therapeutics operates in the pharmaceutical and drug manufacturing industry developing inhibitors of cellular acetylation.
Narendra Lalwani
Executive Vice President of R & D and Chief Operating Officer of Esperion
Narendra Lalwani is Executive Vice President, R & D, and Chief Operating Officer. Prior to joining Esperion, Narendra was Chief Scientific Officer at Cerenis Therapeutics from 2007 to 2014 where he led R&D activities for the company. Previously, Narendra was Vice President of Drug Safety at the original Esperion until its acquisition by Pfizer. Prior to Esperion, Narendra held various positions of increasing responsibility in the Department of Pathology and Experimental Toxicology at Warner-Lambert/Parke-Davis. Narendra is a Fellow of American Heart Association (FAHA) and a diplomate of the American board of Toxicology (DABT).Narendra earned a Ph.D. in Biophysics from the University of Bombay (India) and an MBA from the University of Michigan, Ross School of Business.
Follow Narendra Lalwani:
About Esperion: Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases.
R.J. Demman
COO of Vivera Pharamceuticals
R.J. Demman is the Chief Operations Officer of Vivera Pharmaceuticals. With over 20 years of comprehensive operations, relationship, and business development experience, Mr. Demman is well versed in the needs of high volume Companies. As Vice President of Relationship Marketing with several of the largest gaming institutions, Mr. Demman has crafted a number of high-level programs to increase revenue and growth while maintaining strong bonds with Tribal Councils, government regulators, and team members. Mr. Demman will use his extensive leadership and people skills to oversee the day-to-day operations and implement policies and procedures to promote Vivera’s continued growth.
Follow R.J. Demman:
About Vivera Pharamceuticals: Vivera Pharmaceuticals is an innovative, science-driven pharmaceutical company located in Southern California.
David de Vries
Co-Founder and COO of Arine
David oversees overall company strategy, operations, sales, marketing and business development for Arine. Prior to Arine, David was the Director of Commercial Strategy and Development at Proteus Digital Health, where he oversaw partnerships, key elements of new product development and other strategic growth initiatives including the design and execution of the first value-based contracts for digital medicines. Before that, he worked at the RAND Corporation on the analysis and evaluation of several elements of the Affordable Care Act. When he’s not focusing on transforming healthcare through technology, he is most likely to be spotted at your local photography exhibit, neighborhood pickup basketball court, or by a large body of water attempting and failing some kind of watersport. David holds a Bachelor’s Degree in Neurobiology from Harvard and a Master’s Degree in Chemical Engineering and Biotechnology from the University of Cambridge.
Follow David de Vries:
About Arine: Arine optimizes medications and improves human health through data-driven clinical services.
Tao Fu
President, COO & Director of Zai Lab
Tao Fu has been our President & Chief Operating Officer since September 2018. Prior to joining Zai Lab, he worked with Portola Pharmaceuticals, where he served as Executive Vice President, Chief Commercial and Business Officer, responsible for commercial operations, marketing, sales and business development functions. Prior to joining Portola in June 2015, Tao was Vice President and Head of Mergers & Acquisitions and Alliance Management at Bristol-Myers Squibb (BMS). At BMS, he was responsible for the company’s corporate development, alliance management and venture activities. Between 2003 and 2014, he held several leadership positions with increasing responsibilities at Janssen, the pharmaceuticals group of Johnson & Johnson, most recently as Vice President, Business Development, where he led global M&A activities. He also has experience in business development, commercial strategy and management consulting with McKinsey & Company, Becton Dickinson, etc. Tao holds an M.S. in biology from the University of Rochester and an M.B.A in finance and marketing from Vanderbilt University. He did his undergraduate studies in biology at Tsinghua University in Beijing, China and is a Chartered Financial Analyst (CFA).
Follow Tao Fu:
About Zai Lab: Zai Lab brings transformative medicines for cancer, autoimmune, and infectious diseases to patients in China and around the world.
Michael Russin
Chief Operating Officer (COO) of NexGen Pharmaceuticals
Entrepreneurial, innovative executive who has positioned multiple companies for strong growth after creating targeted business development plans to capitalize on market opportunities coupled with tactical process engineering across operations, systems, and supply chain management. Known for his relentless focus on continuous improvement, operations management, and cost reduction initiatives. He also excels in the areas of marketing, branding, positioning, and product development. Recognized for maximizing performance through the implementation of competitive supply chain management and multi-channel marketing strategies. He is a robust problem solver with a passion for optimizing operations and maximizing profitability. Michael is responsible for all aspects of NexGen’s operations network with a primary focus on continuous improvement, operations management, and customer service as well as quality assurance, and regulatory compliance. He has excelled in driving efficiencies in cost reductions as well as process and systems implementation. Over the years, Michael has been tasked with holistically integrating the Company’s operations with demand, vendor, and fulfillment planning to create synergies in processes and to drive revenue growth. He has also overseen infrastructure development; including NexGen Pharmaceuticals’ current facility that opened in June 2020. He is a results-oriented individual that enjoys identifying issues and digging deep to find solutions in a fact-based manner, using key metrics that have been designed to drive company growth. He views strategy as inseparable from operations; ensuring that every effort expended organizationally supports the strategy of the company. The complexity and diversity of his position is what continues to drive him forward.
Follow Michael Russin:
About NexGen Pharmaceuticals: A Industry leading veterinary compounding pharmacy, offering sterile and non-sterile compounding services nationwide.
John Shannon
Chief Operating Officer of Xeris Pharmaceuticals
Follow John Shannon:
About Xeris Pharmaceuticals: Xeris Pharmaceuticals is a pharmaceutical company that develops therapies for patients in endocrinology, neurology, and gastroenterology.
Jun Yoon
Chief Operating Officer of ShouTi
Jun Yoon is the Chief Operating Officer at ShouTi.
Follow Jun Yoon:
About ShouTi: ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR.
Kamran Tavangar
Chief Operating Officer of Affinivax
Kamran Tavangar has over 20 years of experience in pharmaceuticals and vaccines. Prior to joining Affinivax, Dr. Tavangar was Vice President of Strategic Product Development at Visterra. Dr. Tavangar previously served in various operational and strategic positions with Novartis for 19 years. Most recently he was the Global Head of Strategic Planning at Novartis Vaccines and Diagnostics, subsequent to being Head of Strategic Global Marketing at Novartis Vaccines. Previously, Dr. Tavangar was the Business Unit Head for Novartis Oncology in Australia. He also served as VP Finance for Novartis Pharmaceuticals USA, as well as Head of Investor Relations for Novartis Corporation USA. Dr. Tavangar received his AB in Molecular Biology from UC Berkeley, PhD in Physiology from Stanford University, and MBA from MIT’s Sloan School of Management.
Follow Kamran Tavangar:
About Affinivax, Visterra: Affinivax is a biopharmaceutical company developing vaccines used to enhance the depth of protection against infectious diseases.
Stelios Tzannis
Founder and COO of Aeovian Pharmaceuticals
Stelios Tzannis is the Founder and COO of Aeovian Pharmaceuticals.
Follow Stelios Tzannis:
About Aeovian Pharmaceuticals, Delos Pharmaceuticals: Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Jerry Kuang
COO of HistoWiz
Follow Jerry Kuang:
About HistoWiz: HistoWiz provides automated histopathology for biomedical researchers.
Andrew Miller
Founder & COO of Karuna Therapeutics
Dr. Miller is a Founder, Director, and the Chief Operating Officer of Karuna Pharmaceuticals. Dr. Miller is the lead inventor of Karuna’s KarXT platform and served as CEO of Karuna from 2016-2018. In 2016, Dr. Miller was named one of the top 40 innovators under 40 by MedTech Boston. Previously, Dr. Miller was a Vice President at PureTech Health for 8 years, most recently as Vice President, the COO of Tal Medical, and the acting-COO of Entrega where he serves on the board. Dr. Miller completed his doctoral work in Chemical Engineering at the Massachusetts Institute of Technology and received the MIT Presidential fellow and National Defense Science and Engineering Graduate fellowship awards. Dr. Miller received a B.S. in Chemical Engineering from the University of Illinois with highest honors.
Follow Andrew Miller:
About Karuna Therapeutics, Tal Medical: Karuna Therapeutics is a Massachusetts-based developer of drugs for the treatment of schizophrenia.
Taneli Jouhikainen
COO & President of Savara Pharmaceuticals
Dr. Taneli Jouhikainen is a co-founder of Savara, has served as Chief Operating Officer since October 2009. From October 2006 until September 2009, he served at Akela Pharma Inc., a public clinical stage specialty pharmaceutical company focused on orphan drugs and inhalation products, first as Head of Corporate Development, and subsequently as interim CEO until the company’s merger with Nventa Biopharmaceuticals. From January 2004 to September 2006 he served as President of LAB Pharma Oy, and Head of the Drug Development Business Unit of its parent company, at LAB International, Inc., a public clinical stage specialty pharmaceutical company. From January 2001 to January 2004 he served at Focus Inhalation Oy, a clinical stage specialty pharmaceutical company focusing on inhaled products, first as Vice President of Business Development & Strategy, and subsequently as President & CEO, until the merger of Focus Inhalation with LAB International, Inc. From May 1994 to December 2000, he served at Schering AG, a global pharmaceutical company, first as Research Manager, and subsequently as Head of Clinical Development. Dr. Jouhikainen holds an MD degree, and a Ph.D. degree in hematology and immunology from the University of Helsinki, and an MBA from the Helsinki School of Economics.
Follow Taneli Jouhikainen:
About Savara Pharmaceuticals: Savara Pharmaceuticals develops an inhaled antibiotic for MRSA infection in cystic fibrosis.
Qingsong Zhu
COO of Insilico Medicine
Qingsong Zhu, Ph.D. is the Chief Operating Officer of Insilico Medicine, Inc., a company that utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and biomarker development for aging and age-related diseases. Dr. Zhu received his Ph.D. degree in biochemistry from Kansas State University. Prior to joining Insilico Medicine, he had his postdoctoral training at Johns Hopkins University School of Medicine.
Follow Qingsong Zhu:
About Insilico Medicine: Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.
Babar Ghias
Chief Operating Officer of Castle Creek Biosciences
Babar Ghias is the Chief Operating Officer at Castle Creek Biosciences.
Follow Babar Ghias:
About Castle Creek Biosciences: Castle Creek Biosciences is focused on developing commercializing novel, personalized gene therapies for rare skin disorders.
Ashish Dutt
Executive Director and Chief Operating Officer of BioQuest Solutions
Ashish is Co-founder and Executive Director of BioQuest and brings on to the table his expertise in Pharma Knowledge Outsourcing. His enterprising contribution to BioQuest’s consultative and outstanding problem-solving capability has been the key to designing some of our smart service-solutions for the industry. In the past 15+ years, he has the experience of leading business operations across geographies, from Opportunity Creation to Delivery, thereby building sustainable business models.
Follow Ashish Dutt:
About BioQuest Solutions: BioQuest provides Strategy, Knowledge Solutions and Services.
Jessica Nouhavandi
COO and Co-Founder of Honeybee Health
Follow Jessica Nouhavandi:
About Honeybee Health: Honeybee Health is an online pharmacy selling prescriptions at fair, affordable prices.
Scott Meyers
Chief Operating Officer of Vertice Pharma
Scott Meyers is the Chief Operating Officer of Vertice Pharma. He has over 15 years of pharmaceutical experience, most recently as Vice President, General Manager, Dermatology of Fougera Inc., a Sandoz / Novartis company. Prior to Fougera, Scott led Strategic Planning & Market Analytics for Sandoz US and worked at McKinsey & Company’s pharmaceutical practice in New Jersey, focusing on R&D and commercial operations. Scott also worked as a Chemical Engineer for Merck at their West Point, PA site. Scott holds a Master of Business Administration from Northwestern University’s Kellogg School of Management and holds a Master of Chemical Engineering, a Bachelor of Science in Chemical Engineering, and a Bachelor of Arts in Chemistry all from Cornell University.
Follow Scott Meyers:
About Vertice Pharma: Vertice Pharma is a specialty pharmaceuticals company focused on improving patients’ health.
Keith Westby
Chief Operating Officer of IVERIC bio
Keith Westby is our Vice President of Project Management. Keith has more than 15 years of experience in project and strategic alliance management and manufacturing operations in Biotech companies, two of which executed successful IPOs. Keith was most recently at Pharmasset, Inc., as Director, Project and Alliance Management, accountable for developing and implementing strategy across manufacturing, research and development, preclinical, clinical, regulatory, and finance for both internal and partnered projects. Prior to that Keith served in positions of increasing responsibility at Eyetech Pharmaceuticals, most recently as Director, Alliance & Project Management, leading multifunctional project teams in the NDA filing and marketing approval of Macugen® for Age-Related Macular Degeneration. Previously, Keith was at Tunnell Consulting, where he was a Senior Consultant in the firm’s Life Sciences practice focused on manufacturing operations and process improvement. Keith holds a B.S. in Applied Physics from the State University of New York, College at Geneseo, an M.S. in Engineering Management from Drexel University, and an MBA from Columbia Business School.
Follow Keith Westby:
About IVERIC bio: IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
Alex Hurd
Chief Operating Officer of ClarusONE Sourcing Services
Follow Alex Hurd:
About ClarusONE Sourcing Services: ClarusONE Sourcing Services is involved in the strategic sourcing of generic pharmaceuticals at a competitive cost to meet consumer demand.
Michael McElhaugh
Co-Founder and Chief Operating Officer of Arbutus Biopharma
Mr. Michael J. McElhaugh, also known as Mike, co-founded Arbutus Biopharma Inc. in 2012 and serves as its Chief Operating Officer. Mr. McElhaugh has over 15 years of combined scientific and business experience. Prior to co-founding OnCore Biopharma, Inc., he was most recently Director of Hepatitis C Worldwide Commercialization at Bristol Myers Squibb where he was responsible for global hepatitis C commercialization. Prior to Bristol Myers Squibb, he was Director, Business Development and Market Analytics at Pharmasset, Inc., where he was an integral contributor to corporate strategy, strategic marketing and business development efforts. He played a key role in the sale of Pharmasset to Gilead Sciences, leading all diligence efforts and commercial analyses. Prior to joining Pharmasset, he held roles of increasing responsibility in Market Research at Viropharma, Inc., and at Merck and Co, Inc. and Thomas Jefferson University as a bench scientist. He holds a B.S. in Psychology from the Saint Joseph’s University, a M.S. in Microbiology from Thomas Jefferson University and an MBA from Cornell University.
Follow Michael McElhaugh:
About Arbutus Biopharma: Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Marie Crump
Chief Operating Officer of DATUM LLC
Follow Marie Crump:
About DATUM LLC: DATUM provides the first data governance and stewardship solution to visibly link the value of a data policy to its impact on the business.
Jessica A. Iannotta
Chief Operating Officer of Savor Health
Jessica is a registered dietitian and certified specialist in oncology nutrition (CSO). She studied nutrition at Cornell University and completed her dietetic internship at New York Presbyterian Weill Cornell Medical Center. She obtained her Master’s degree through the University of Medicine and Dentistry of New Jersey. Jessica has worked in inpatient and outpatient oncology settings since 2001 in the North Shore-LIJ Health System. Jessica is in charge of all operations including clinical and culinary operations ranging from menu development to evidence-based website content, relationships with registered dietitians and social workers and developing processes and protocols for intake, management and outcomes analysis of patients.
Follow Jessica A. Iannotta:
About Savor Health: B2B digital therapeutic providing personalized nutritional strategies to prevent and manage the symptoms and side effects of cancer.
Chad Pytel
Founder & COO of thoughtbot
Chad Pytel leads the day-to-day operations of thoughtbot, including human resources, hiring, and growth, and is responsible for overall strategy for the company. He has fifteen years of experience in software development and services, and has co-authored two books: Rails AntiPatterns and Pro ActiveRecord for Ruby. Chad holds bachelor of science degrees in both Computer Science and Humanities & Arts (Drama/Theatre) from Worcester Polytechnic Institute (WPI).
Follow Chad Pytel:
About thoughtbot, thoughtbot: thoughtbot is a consulting firm that offers end-to-end web and mobile product development services.
Brian Jackson
President & COO of burstIQ
Brian has played a key role in the development of the BurstIQ platform, and leads network engineering and technical operations for the company. An expert in security and enterprise cloud infrastructure platforms, Brian has been published in numerous works and has mentored large-scale Engineering, DevOps, and Development teams. Prior to joining BurstIQ, Brian led Cloud Engineering for an enterprise healthcare solution provider and provided consulting expertise to numerous Fortune 500 companies. Brian has a B.S. in Information Technology from Kansas State University.
Follow Brian Jackson:
About burstIQ: A health-focused enterprise enablement and global network that connects businesses and people through the power of blockchain.
Christopher White
Chief Operating Officer of HealthCare Royalty Partners
Mr. White is responsible for leading the strategic direction, business development and corporate finance activities of Janney’s Investment Banking Division within the Capital Markets Group. Prior to joining Janney in 2011, Mr. White worked at Cowen Group, Inc. where he held a number of senior management positions including Chief of Staff, Chief Financial Officer and Chief Operating Officer. Mr. White also served as a member of the Operating Committee at Cowen and was a member of the Investment and Operating Committees of Cowen Healthcare Royalty Partners. From 2003 to 2005, Mr. White served as a member of SG Capital Partners, the Merchant Banking Division of Cowen and Company. Before joining the Merchant Banking Division, Mr. White was a senior calling officer covering the Technology and Consumer sectors in the Equity Capital Markets Group of Cowen and Company, which he joined in 1999. Mr. White has also worked at Salomon Smith Barney in the Equity Capital Markets Group and has seven years experience as a practicing securities and mergers and acquisitions lawyer. Mr. White is a graduate of Amherst College and holds a J.D. from the University of Michigan Law School.
Follow Christopher White:
About HealthCare Royalty Partners: HealthCare Royalty Partners is a global investment firm that partners with healthcare companies, non-profit institutions and inventors.
G. Bradley Cole
COO of Genomic Health
Follow G. Bradley Cole:
About Genomic Health: Genomic Health is a provider of genomic-based diagnostic tests that address overtreatment and optimal treatment of early-stage cancer.
David G. Watumull
Chief Operating Officer of Cardax Pharma
Follow David G. Watumull:
About Cardax Pharma: Cardax Pharma offers small molecule therapies for unmet medical needs such as hepatitis, arthritis, cardiovascular diseases, and more.
Weiqing Zhou
Co-founder & COO of FogPharma
Follow Weiqing Zhou:
About FogPharma, LifeMine Therapeutics: FogPharma creates a new class of medicines that target human disease drivers currently considered undruggable.
Glenn Gerecke
Chief Operating Officer of Phlow
Glenn Gerecke is the Chief Operating Officer at Phlow.
Follow Glenn Gerecke:
About Phlow: Phlow supplies affordable, quality, essential medicines through U.S.-based advanced manufacturing processes.
Michael Metzger
President & Chief Operating Officer of Syndax Pharmaceuticals
Metzger brings to Mersana nearly 20 years of experience within the life sciences and pharmaceuticals industries. At Forest Laboratories, he led the mergers and acquisitions function, where he completed deals with Cerexa and Novexel, together forming the cornerstone of Forest’s hospital antibiotic franchise, and most recently led the successful acquisition of Clinical Data, Inc. He also led the US co-development and co-promotion deal with Ironwood Pharmaceuticals for Linaclotide. Prior to Forest, Mr. Metzger was Vice President of Corporate Development at Onconova Therapeutics, where he was responsible for the company’s business development and financial initiatives. He also served as Managing Director at MESA Partners, a venture capital firm focused on healthcare and IT companies. He serves as a member of the Board of Directors and Chairman of the Finance Committee of Response Genetics, Inc., (NASDAQ: RGDX) a company focused on the development and commercialization of molecular diagnostic tests for cancer. Mr. Metzger earned his B.A. from George Washington University and an M.B.A. in Finance from New York University’s Stern School of Business.
Follow Michael Metzger:
About Syndax Pharmaceuticals: Syndax Pharmaceuticals focuses on developing an HDAC inhibitor for solid tumors and hematological tumors.
Mohammad N. Noshi
Co-founder, President of R&D and Chief Operating Officer of Akanocure Pharmaceuticals, Inc.
https://www.akanocure.com/noshi.html
Follow Mohammad N. Noshi:
About Akanocure Pharmaceuticals, Inc., Akanocure Pharmaceuticals, Inc.: Akanocure is a drug development company with a focus on orphan and unmet needs in oncology.
William Kent
Co-Founder, President & Chief Operating Officer of MedAware Systems
William brings over 30 years of experience in both domestic and international business and market development, working with a broad range of technology and industrial companies, from start-ups to Fortune 200 companies. William has worked with leading companies from India, China, Japan, Canada, the US, and Western Europe to develop business models and marketing strategies in a wide range of geographic and vertical markets. William is passionate about pairing the right products in the right markets to position companies for growth and to bring value to consumers. As president of a mid-west based business practice consulting company, William successfully worked with his clients to define markets for their products, develop manufacturing and distribution practices, develop customer service strategies, define launch strategies, and grow market share. Most recently William worked as the Senior VP of Boulder Imaging. William led the product development and operational development for BI to transition the company from R&D to product manufacturing. Previously William led the development of a technology company in the electric vehicle market to design and develop state-of-the-art vehicle management systems.William has worked with a variety of companies to develop products and market strategies such as Liqui-Met, Novaflow Systems, Micro-Metal, Soujanya Enterprises, Parekh Group, Virttel and Motostorm. For each of these companies William defined vertical markets, created market development plans and built market share. William is an avid jogger, cyclist and golfer. William is a strong advocate of corporate social responsibility and is committed to building companies that make a positive contribution to the communities in which they operate.
Follow William Kent:
About MedAware Systems: MedAware Systems is a medical research data company delivering analysis of all available data on any medical topic.
Willem De Goede
COO of B. Braun Medical
Willem De Goede is the Chief Operating Officer at B. Braun Medical
Follow Willem De Goede:
About B. Braun Medical: B. Braun Medical is a medical device manufacturing company that specializes in infusion therapy and pain management.
Eniko Fodor
COO of Verseon
Eniko Fodor serves as the Chief Operating Officer at Verseon. Eniko has guided Verseon’s technology and drug pipeline development and operational growth and has also overseen its finance and accounting functions through various stages. Previously, she was co-founder and COO of Pulsent Corp. An inventor of that company’s original technology, she was instrumental in growing the company and developing its products and technology. Eniko is an inventor on 25 patents and received her BS in physics from Universitatea Babes-Bolyai, Kolozsvár, Romania
Follow Eniko Fodor:
About Pulsent Corporation, Verseon: Verseon’s breakthroughs in computational chemistry, AI, & synthesis create novel pharmaceuticals. Atom by atom, we drive innovation.
Wendy S. Johnson
Chief Operating Officer of Reneo Pharmaceuticals
Wendy S. Johnson is a venture partner with ProQuest Investments, and the CEO of two San Diego-based companies, Aires Pharmaceuticals and Palkion. She has broad experience in the establishment and operations of venture-backed life science companies. Working with life science start-up companies since 1986, she has established a broad network of contacts including venture capital organizations, high level individuals involved in research and development as well as business development in the major pharmaceutical companies and biotechnology companies throughout the world. In addition to these business contacts, she is well-known in the technology transfer offices of many of the leading academic and research institutions in the U.S. and Europe. After leaving a ten-year career with the Food and Drug Administration she became involved in the biotechnology industry working in a number of start-up venture backed companies. She joined ProQuest Investments, a $1B life science venture fund as a venture partner in October 2005. In November 2006, she founded Aires Pharmaceuticals a pulmonary drug development company and secured Series A financing. In February 2007 she founded Palkion, Inc. a joint venture company with a Crystal Genomics, Inc. a public biotechnology company in South Korea, and secured series A financing. Prior to ProQuest she served as Senior Vice President, Corporate of Salmedix until its sale to Cephalon in May 2005. She has served as part of senior management teams in several San Diego-based life science companies since 1988. Ms. Johnson holds an M.B.A. from Loyola University, an M.S. in clinical microbiology from the Hahnemann Medical School and a B.S. in microbiology from the University of Maryland.
Follow Wendy S. Johnson:
About Gemini Advisors, Palkion, Reneo Pharmaceuticals: Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.
Karen Brennan
Chief Operating Officer of Checkmate Pharmaceuticals
Follow Karen Brennan:
About Checkmate Pharmaceuticals: Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
Harvey Horswell
Chief Operating Officer of 21st Century Medicine
Harvey J. Horswell is Chief Operating Officer for 21st Century Medicine. He has operational and financial responsibilities for day-to-day business decisions and fully participates in the strategic mission of the company. He brings more than twenty years of proven leadership experience establishing corporate policy and objectives, designing quality systems and performing risk analysis. Most recently the Corporate Supply Chain Manager for PGP Industries, Inc. in Santa Fe Springs, CA., Mr. Horswell managed precious metal logistics and directed customer service and material control functions creating doubled profitability. Previously Mr. Horswell served as a General Manger, Quality Manager, Production & Development Manager and Analytic Services Manager. A native of Iowa and raised in Minnesota, Mr. Horswell holds a B.S. in Chemistry from Ambassador College in Pasadena, California, attended the University of Southern California, and is an ABD, Ph.D. in Chemistry. He has attended numerous postgraduate seminars on topics from statistics to experiment design and is a member of the American Chemical Society and the American Society for Quality.
Follow Harvey Horswell:
About 21st Century Medicine: 21st Century Medicine has developed an entire platform technology focused on the creation and commercialization of hypothermic preservation.
D. Jeffrey Keyser
Co-Founder, President, and COO of Renibus Therapeutics
Jeff co-founded ZS Pharma in 2008 and has over 30 years of experience in the pharmaceutical industry. Prior to joining ZS Pharma, Jeff served as the Chief Compliance Officer and Vice President of Regulatory Affairs at Encysive Pharmaceuticals. In addition, he served as Vice President of Development and Regulatory Affairs at Adams Respiratory Therapeutics and held senior management positions at Medeva Americas, Marion Merrell Dow, Marion Laboratories and Abbott Laboratories. Jeff has experience in regulatory, medical, clinical and product development and has directed efforts to develop, prepare and secure approvals of numerous INDs and NDAs/MMAs in the United States, Canada, Australia and Europe. Jeff received his B.S. degree in pharmacy and his J.D. from Creighton University. He earned an M.P.A. from the University of Missouri at Kansas City and a Ph.D. in economics from the University of Texas at Dallas
Follow D. Jeffrey Keyser:
About Renibus Therapeutics, ZS Pharma: Renibus Therapeutics operates in the healthcare industry focusing on the pharmaceutical business.
David Hahn
Chief Operating Officer of The Medical Affairs Company
Follow David Hahn:
About The Medical Affairs Company, The Medical Affairs Company: The Medical Affairs Company offers biopharmaceutical, medical device and diagnostics.
Robert Odell
President & Chief Operating Officer (COO) of Cardiac Insight
With broad operating, product development, strategy and regulatory/quality experience, Odell has held executive positions at General Electric, Medtronic, Analogic Corporation and Siemens. Prior to working with Cardiac Insight, he was CEO and COO of Cardiac Science Corporation and Criticare Systems Inc., leaders in the defibrillation and patient monitoring markets.
Follow Robert Odell:
About Cardiac Insight: Cardiac Insight is a privately-held medical device company that offers body-worn ECG sensing technology.
Bradley L Campbe
Chief Operating Officer of Amicus Therapeutics
Bradley L. Campbell joined Amicus in May 2006 and currently serves as Chief Operating Officer. He brings 15 years of experience in the biotech and pharmaceutical industries. Prior to Amicus, Mr. Campbell was with Genzyme Corporation, where he first served as Sr. Product Manager for Myozyme®, an enzyme replacement therapy for Pompe disease. He then became a Business Director in Genzyme Cardiovascular, responsible for business development, alliance management and commercial planning for their cardiac gene therapy programs. Mr. Campbell has also worked in sales & marketing for Bristol-Myers Squibb and as a business strategy consultant for Marakon Associates.
Follow Bradley L Campbe:
About Amicus Therapeutics: Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
H. Lee Warren
Chief Operating Officer of US WorldMeds
Follow H. Lee Warren:
About US WorldMeds: US WorldMeds is a closely-held, Kentucky-based specialty pharmaceutical company. Our mission is to develop, license and commercialize
Micah Litow
President and COO of Kalderos
Micah Litow is Kalderos’ Chief Operating Officer.
Follow Micah Litow:
About Kalderos: Kalderos provides a SaaS based drug discount management solution, which identifies, checks, and resolves non-compliance.
David Darst
Chief Operating Officer of Inspirna, Inc.(formerly Rgenix, Inc.)
Follow David Darst:
About Inspirna, Inc.(formerly Rgenix, Inc.): Inspirna is a biotechnology company developing drugs for the treatment of cancer.
Azmi Nabulsi
Chief Operating Officer & Co-founder of Phathom Pharmaceuticals
Azmi Nabulsi, a physician and public health professional, is a seasoned global corporate executive with a successful track record in pharmaceutical research and development. He is currently Entrepreneur in Residence (EIR) at Frazier Healthcare Partners in Palo Alto, CA. This followed a 14-year career at Takeda Pharmaceuticals marked by industry-leading innovations and transformational accomplishments. At Takeda, he served as both the deputy chief medical and scientific officer of Company Limited, one of the 20 largest pharmaceutical companies in the world, and R&D head of strategic and professional affairs. In these roles, he led all R&D medical and operations functions, oversaw a $3 billion global portfolio, and managed a staff of over 1000 and budget of $450 million. During his 14-year career at Takeda, in the U.S. and Japan, Azmi Nabulsi has overseen global drug development for both early and late stage agents, bringing the majority of Takeda’s 21 new drugs in multiple therapeutic areas and countries to market from 2005 to 2015. He is also responsible for the design and execution of the company’s major R&D transformation utilizing industry-leading approach to drive innovation; in addition, he led the creation of the first global Biotechnology Innovation Park in Japan. Azmi Nabulsi has led or directed partnerships and alliances in oncology, immunology, and cardiovascular medicine and metabolism. His impact extends to investor relations, regulatory affairs, crisis management and stakeholder relations, including patient advocacy. From 2009 to 2013, Azmi Nabulsi played a key role in transforming Takeda’s organization and culture following acquisitions of Millenium, Nycomed, and TAP. From 2006 to 2009, Azmi Nabulsi worked in Japan as the company’s general manager of strategic development, where he oversaw global development and regulatory strategy for all Takeda products as well as portfolio strategy and R&D alliance management. He was also instrumental in the globalization efforts of Takeda R&D. From 2004 to 2006, Azmi Nabulsi held leadership positions in R&D Operations. Azmi Nabulsi is a member of the boards of directors of the Foundation for Sarcoidosis Research. He previously served on the board of directors for the Illinois Science and Technology Coalition, iBio Institute, and Rosalind Franklin School of Medicine and Science College of Pharmacy and has held academic appointments in epidemiology at the University of North Carolina at Chapel Hill and the University of Minnesota. Azmi Nabulsi has an M.D. from Ain-Shams University, Cairo, Egypt, and a M.P.H. from the University of Minnesota. His professional affiliations include the Chief Medical Officers Executive Summit & Roundtable; International Society of Pharmacoeconomics and Outcomes Research (ISPOR); American Society of Clinical Oncology (ASCO); and the American Heart Association (AHA). He is the author of or cited in over 25 scientific publications.
Follow Azmi Nabulsi:
About Phathom Pharmaceuticals: Phathom Pharmaceuticals is a biopharmaceutical company.
Connie Lebakken
Founder ,President & COO of Stem Pharm
Connie Lebakken is the Founder & President of stem pharma.
Follow Connie Lebakken:
About Stem Pharm: Stem Pharm’s synthetic biomaterials support the optimization of cell expansion.
Willis C. Lee
Chief Operating Officer of Emmaus Medical
Mr. Lee has more than 25 years of management and consulting experience with influential companies in the semiconductor and healthcare industries. Prior to joining Emmaus, Mr. Lee led worldwide sales and business development of Yield Dynamics’ product group at MKS Instruments. He joined the Comapany in 2009 and has served as Chief Operating Officer since May 2011. He has held various managerial and senior positions at companies including HPL, Syntricity and Reden & Anders, a subsidiary of United Healthcare that provides actuarial services including capitation and risk assessment analyses for healthcare insurance carriers. Mr. Lee received his B.S. and M.S. in Physics from University of Hawaii and University of South Carolina, respectively. He was a member of the American Physical Society, completed TQM/SPC programs, and has published papers in Nuclear Instruments and Methods.
Follow Willis C. Lee:
About Emmaus Medical: Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
David Duranceau
Co-Founder and COO of PharmRight
Follow David Duranceau:
About PharmRight: PharmRight specializes in providing products and services that maximize medication adherence at home.
A. Taylor Bright
Co-Founder and Chief Operating Officer of Novoron Bioscience
Taylor Bright’s passion lies in the translation of exciting academic science into clinically viable commercial applications. As a co-founder of Novoron Bioscience, Taylor Bright has applied this passion into leveraging his academic and industry experience to advance Dr. Stiles’ discoveries out of UCSD and into Novoron Bioscience’s technology pipeline. His extensive research experience in cell biology, cell culture, and molecular biology is well-served by his competency in bioinformatics and computational biology. In addition, he has experience in protocol design and optimization as well as project management. Taylor earned a Ph.D. in Biomedical Science from UCSD and an A.B. from Princeton University.
Follow A. Taylor Bright:
About Novoron Bioscience: Biotechnology company developing pharmaceutical therapies for nerve regeneration in the central nervous system.
Shawn Gahr
Co-Founder, COO & CFO of Novoron Bioscience
Shawn Gahr is a co-founder of Novoron Bioscience. Shawn Gahr has over a decade of experience in financial analysis, business development, and project management with high-profile start-up companies, such as Apptio and Imperium Renewables. Shawn earned an M.P.I.A. in International Economics from UCSD, a B.S. in Business-Economics from Willamette University and holds a Certificate in Biomedical Regulatory Affairs from the University of Washington.
Follow Shawn Gahr:
About Novoron Bioscience: Biotechnology company developing pharmaceutical therapies for nerve regeneration in the central nervous system.
Nicholas Cucinelli
COO of iReprogram
Nicholas Cucinelli currently works as the COO for iReprogram.
Follow Nicholas Cucinelli:
About iReprogram: iReprogram is a cell regeneration lab that aims to expedite the delivery of next-generation personalized medicine.
Douglas Bonhaus
Chief Operating Officer of Neuropore Therapies
Chief Executive Officer at Neuropore Therapies, Inc.
Follow Douglas Bonhaus:
About Neuropore Therapies, Neuropore Therapies: San Diego-based Neuropore, a biopharmaceuticals firm developing treatments for Parkinson’s disease.
Douglas Bonhaus
Chief Operating Officer of Neuropore Therapies
Chief Executive Officer at Neuropore Therapies, Inc.
Follow Douglas Bonhaus:
About Neuropore Therapies, Neuropore Therapies: San Diego-based Neuropore, a biopharmaceuticals firm developing treatments for Parkinson’s disease.
Matthew B. Boxer
Co-Founder and Chief Operating Officer of Veralox Therapeutics
Matthew Boxer has more than 10 years of drug discovery, research and development experience following a career at the NIH, most recently at NCATS, where he was Medicinal Chemistry Group Leader. At NCATS, he led interdisciplinary teams responsible for small molecule hit-to-lead and lead-optimization for over 25 projects across a wide range of indications, with a large focus on rare diseases. Recently, Matthew Boxer was project lead on a multi-institutional drug discovery project that delivered a clinical product candidate for advancement to investigational new drug (IND)-enabling studies. Matthew Boxer has managed collaborations with more than 30 external investigators from academia, NIH, and the biotechnology sector in the US and abroad. He is an inventor on 13 patents, with multiple patents licensed by biotechnology companies. Matthew Boxer earned a Bachelor of Science in Chemistry from the University of Vermont and a Ph.D. in Chemistry from the University of Chicago. He received postdoctoral training at the NIH within the division of preclinical innovation. Matthew Boxer currently reviews for several journals, grant organizations, government and foundations with a focus on drug discovery.
Follow Matthew B. Boxer:
About Veralox Therapeutics: Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.
Byron Wittenberg
COO & CFO of Epivara
Byron Wittenberg serves as the Chief Operating and Financial Officer at Epivara.
Follow Byron Wittenberg:
About Epivara: Epivara provides a single-injection alternative to spay and neuter surgery.
Tamas Gorbe
Co-Founder and COO of Menten AI
Tamas Gorbe serves as a co-founder and COO at Menten AI.
Follow Tamas Gorbe:
About Menten AI: Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
John Wilson
Chief Operating Officer of Rapid Micro Biosystems
John Wilson is the Chief Operating Officer at Rapid Micro Biosystems.
Follow John Wilson:
About Rapid Micro Biosystems: Rapid Micro Biosystems offers tools that detect microbial contamination in manufacturing pharmaceutical, biotechnology and other products.
John Dykstra
COO of Humanetics Corporation
Follow John Dykstra:
About Humanetics Corporation, MetaLogics: clinical stage pharmaceutical company.
Robert Palmer
Chief Operating Officer of Wedgewood Pharmacy
Bob Palmer, chief operating officer for Wedgewood Pharmacy, has full strategic and operational accountability for Business Operations and Information Technology. As a member of the Wedgewood Pharmacy leadership team, he is accountable for performance measures and for marshaling available resources to the most productive uses, with the aim of creating maximum value for the company and its customers. He has been in the information technology profession since 1989. Prior to joining Wedgewood in 2011, he was senior vice president and CIO for Franklin Credit Management Corporation (Jersey City, NJ); vice president, IT and CIO for Brown-Forman Corporation-Lenox Group, Inc. (Bristol, PA); senior programmer analyst for Johnson & Johnson-Janssen Pharmaceutica (Titusville, NJ); and lead analyst for Emerson Quiet Kool (Woodbridge, NJ). Palmer holds a B.S. degree in Management from Rowan University (Glassboro, NJ); and an M.B.A. degree from Rider University (Lawrenceville, NJ). He received a post-graduate Darden Partnership certificate from the Darden Graduate School of Business from the University of Virginia (Charlottesville, VA).
Follow Robert Palmer:
About Wedgewood Pharmacy: Wedgewood Pharmacy is a PCAB accredited compounding pharmacy.
Nicholas Hodge
President & Chief Operating Officer of SeaChange Pharmaceuticals
Nick Hodge received a Ph.D. in Organic and Analytical Chemistry from Cornell University. He has held senior leadership positions at DuPont Merck, Caliper Technologies, Amphora Discovery (founder) and Ruga. Inventions from his corporate R&D labs include drugs for human clinical trials in several therapeutic areas, computational methods for drug design, and biological screening technology. Nick has extensive experience in the conception and execution of platform drug discovery startups, including commercialization strategy, fund-raising, business development, sales and management.
Follow Nicholas Hodge:
About SeaChange Pharmaceuticals: SeaChange develops chemoinformatic and statistical methods to uncover links between drug molecules and the biological targets.
Nicholas Hodge
President & Chief Operating Officer of SeaChange Pharmaceuticals
Nick Hodge received a Ph.D. in Organic and Analytical Chemistry from Cornell University. He has held senior leadership positions at DuPont Merck, Caliper Technologies, Amphora Discovery (founder) and Ruga. Inventions from his corporate R&D labs include drugs for human clinical trials in several therapeutic areas, computational methods for drug design, and biological screening technology. Nick has extensive experience in the conception and execution of platform drug discovery startups, including commercialization strategy, fund-raising, business development, sales and management.
Follow Nicholas Hodge:
About SeaChange Pharmaceuticals: SeaChange develops chemoinformatic and statistical methods to uncover links between drug molecules and the biological targets.
Andrew Bane
COO of VetSource
Andrew Bane currently serves as Chief Operating Officer of VetSource. As a member of the founding team of VetSource, Bane has been intimately involved in shaping the strategic direction of VetSource and has held many positions in the company since its inception in 2005.
Follow Andrew Bane:
About VetSource: VetSource is a pharmaceuticals company providing pet care medication and vaccination services.
Maria Sippola- Thiele
Chief Operating and Business Officer of Chaperone Therapeutics
Maria Sippola-Thiele serves as the Chief Operating and Business Officer at Chaperone Therapeutics. Maria brings a wealth of expertise in business development and intellectual property management to Chaperone, having served as the Associate Director of the first Human Genome and Gene Therapy Center at the University of Michigan Medical Center under the Direction of Francis Collins, as Associate Director of the University of Michigan Medical Center Technology and Corporate Research Office and as Assistant Dean for Business Development at the Duke University School of Medicine. She has served as a founder and in other leadership positions in biotechnology and therapeutic development companies. Dr. Sippola-Thiele received her Ph.D. in Biochemistry from the University of Turku, Finland, carried out Postdoctoral training at the National Cancer Institute, National Institutes of Health and earned her MBA from the University of Michigan Ross School of Business.
Follow Maria Sippola- Thiele:
About Chaperone Therapeutics: Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding
Jim Iversen
CEO and COO of Sen-Jam Pharmaceutical
Jim is a Senior Executive with a consistent track record of developing and executing business strategies that deliver rapid growth in sales, profits, market share, employee and customer satisfaction. Client engagements range from start-ups to late stage, often resulting in an M&A transaction.
Follow Jim Iversen:
About Sen-Jam Pharmaceutical: Sen-Jam Pharmaceutical is a medical company developing novel pharmaceutical solutions for large unmet needs using the development pathway.
Christopher Pirie
Co-Founder & COO of HDT Bio
Follow Christopher Pirie:
About HDT Bio: IMMUNE THERAPY FOR ALL: We’re transforming inventive immunotherapies for oncology and infectious disease.
Krzysztof Appelt
Founder & Chief Operating Officer of Prevacept Infection Control
Dr. Appelt is a seasoned bio-technology scientist and executive with over 25 years of management experience in the biopharmaceutical industry. He has had extensive experience in the discovery and development of antiviral, antibacterial and anticancer chemotherapeutic agents. Dr. Appelt lead a multidisciplinary team at Agouron Pharmaceuticals which discovered and developed ViraceptTM – an innovative AIDS therapy, and several other compounds discovered using structure-based approached pioneered by Agouron. After Agouron’s acquisition by Warner-Lambert and subsequent merger with Pfizer, Dr. Appelt served as Global Head of Ophthalmology in both organizations. From 2001 to 2005 Dr. Appelt served as Executive VicePresident and Chief Technology Officer at Quorex Therapeutics, a company focused on the discovery of antibacterial and antibiofim agents. Dr. Appelt founded Great Lakes Pharmaceuticals in 2006. Dr. Appelt received his undergraduate degree in Physiology from Poznan University in Poland and his Ph.D. in Biophysics from the Max Planck Institute in West Berlin. Before joining Agouron Pharmaceuticals in 1987 he was Assistant Professor in Chemistry Department in University of California in San Diego. Dr. Appelt is a co-author of 57 peer reviewed publications and co-inventor of several patents.
Follow Krzysztof Appelt:
About Prevacept Infection Control: Prevacept Infection Control is a clinical-stage company focused on developing.
Mendy Schurder
COO of LGM Pharma
Follow Mendy Schurder:
About LGM Pharma: LGM Pharma, an innovation-driven company involved in distribution of cGMP active pharmaceutical ingredients.
Marc Foster
Co-Founder & COO of Transparency Life Sciences
Follow Marc Foster:
About 1910 Genetics, Transparency Life Sciences: Transparency Life Sciences is a world’s first drug development services company based on open innovation.
Jing Wang
Co Founder & COO of iLabService
Follow Jing Wang:
About iLabService: ILabService simplifies lab operation by using IoT and AI technologies.
Carolyn Durham
Chief Operating Officer of ProPharma Group
Carolyn Durham is the Chief Operating Officer at ProPharma Group.
Follow Carolyn Durham:
About ProPharma Group: ProPharma Group is the independent, single-source provider of regulatory, compliance, pharmacovigilance, and medical information services.
Walter Piskorski
COO of Euthymics Bioscience
Follow Walter Piskorski:
About Euthymics Bioscience: Euthymics Bioscience, a neuroscience-focused biopharmaceutical company, develops medicines for central nervous system disorders.
Josh Spiegel
Chief Operating Officer of NeuroCog Trials
Follow Josh Spiegel:
About NeuroCog Trials, VeraSci: NeuroCog Trials is the leading cognition services company for the pharmaceutical industry.
Jacqueline Johnson
Co-Founder and Chief Operating Officer of Sydnexis
Jacqueline Johnson, Ph.D. is co-founder and chief operating officer of Sydnexis. Her role includes but is not limited to the management of finance, manufacturing, preclinical toxicology studies, analytical chemistry, and quality programs for the Company. Prior to Sydnexis, Johnson was president of development and strategic consulting LLC for 10 years. This firm offered management expertise to biotechnology clients in the areas of regulatory and clinical affairs. In addition, Johnson held interim management roles in biotech start-ups as acting CEO of Trinity Pharmaceutical and acting COO of Revision Therapeutics. Johnson received both a bachelor and a master degree from the University of California, Berkeley, a Ph.D. from Stanford University School of Medicine (Genetics) and as a Damon Runyon Fellow did her Post-doctoral work at The Salk Institute.
Follow Jacqueline Johnson:
About Sydnexis: Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia.
Jim Herrmann
CFO / COO of Cour Pharmaceuticals Development
Jim is a financial and operations executive with over 25 years experience spanning finance, product development, manufacturing and regulatory, in both diagnostics and therapeutics. Jim co-founded Tolera Therapeutics, where he worked with CEO John Puisis to raise $20 million and bring its MAb therapy from pre-clinical to a Phase 3 Special Protocol Assessment. Prior to this, Jim served as CFO for Third Wave Technologies (NASDAQ: TWTI), where he oversaw long-range and annual planning, company-wide systems and infrastructure development, operational management as well as quality system oversight. Jim oversaw the company’s first FDA 510k filing for a molecular diagnostic and the launch of its multiplexing diagnostic platform. Jim is a graduate of the University of Notre Dame and the University of Chicago (MBA).
Follow Jim Herrmann:
About Cour Pharmaceuticals Development: Cour Pharmaceuticals Development is developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.
Lei Jin
Chief Operating Officer of Wuxi Biortus Biosciences
Lei Jin is the Chief Operating Officer at Wuxi Biortus Biosciences.
Follow Lei Jin:
About Wuxi Biortus Biosciences: Wuxi Biortus Biosciences is an innovation-driven contract research organization committed to high-quality R&D services in drug discovery.
Hillary Peckham
Chief Operating Officer of Etain
Hillary Peckham co-founded Etain, LLC, the only women-owned business to receive one of the five competitive medical marijuana licenses in New York State. When awarded the license at 24 years old, this made Hillary the youngest person to ever receive one a competitive marijuana license in the Unites States. Hillary and her co-founders built an application and operations strategy founded on small-scale, deliverable plans with room to grow and a commitment to economic development as well as quality of life for patients in New York State. Etain opened it’s dispensaries to patients within five months of being awarded a license, with more products than any other marijuana company in New York, and is the second company to open all four of its allocated dispensing locations around New York State. In addition to her role as owner, Hillary is the Chief Operating Officer and oversees all operations for Etain, LLC at their manufacturing facility and 4 dispensing locations. She is the acting spokeswoman for the company as well as liaison between Etain, LLC and the NYS Department of Health.
Follow Hillary Peckham:
About Etain, Peckham Industries, Inc.: Etain LLC is a women owned family business operating within New York State.
Henric Bjarke
Senior Vice President & COO of Inozyme
Henric Bjarke is chief operating officer at Inozyme Pharma
Follow Henric Bjarke:
About Enobia Pharma, Inozyme: Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially.
Michael Dale
Co-Founder, President, Chief Operating Officer of Personalized Stem Cells
Michael Dale is the Co-Founder, President, and Chief Operating Officer at Personalized Stem Cells.
Follow Michael Dale:
About Personalized Stem Cells: Personalized Stem Cells is a Biotechnology company that provides quality stem cell processing services.
Michael Dale
Co-Founder, President, Chief Operating Officer of Personalized Stem Cells
Michael Dale is the Co-Founder, President, and Chief Operating Officer at Personalized Stem Cells.
Follow Michael Dale:
About Personalized Stem Cells: Personalized Stem Cells is a Biotechnology company that provides quality stem cell processing services.
Bob Schroff
Chief Operating Officer of Imhotex
Follow Bob Schroff:
About Imhotex: Imhotex is a virtual biopharmaceutical business working on Crohn’s disease treatments.
Travis Witzke
Founder & COO of Desert Valley Tech
Travis Witzke currently works as the Founder and COO for Desert Valley Tech.
Follow Travis Witzke:
About Desert Valley Tech: Desert Valley Tech develops a cold chain storage system for blood, pharmaceuticals, biologics, organs, and other items.
Brian Hilbush
Chief Operating Officer of ModGene Pharma LLC
Follow Brian Hilbush:
About ModGene Pharma LLC: ModGene Pharma, LLC is a preclinical stage pharmaceutical company developing therapeutics for the prevention of Alzheimer’s disease.
Brian Hilbush
Chief Operating Officer of ModGene Pharma LLC
Follow Brian Hilbush:
About ModGene Pharma LLC: ModGene Pharma, LLC is a preclinical stage pharmaceutical company developing therapeutics for the prevention of Alzheimer’s disease.
Roger Nolan
Co-Founder, President and COO of BioKier
Roger Nolan is responsible for the development of BioKier’s drug candidates for type 2 diabetes, including capital-raising, preclinical, clinical and regulatory strategy, and management of consultant and strategic partner interactions. Dr. Nolan is experienced in management of preclinical and clinical drug development programs, regulatory strategy and interactions, evaluation of new technologies for in-licensing, and outsourcing to specialist service providers. His specific areas of expertise are in diabetes, oncology and cardiovascular indications. Previous positions held by Dr. Nolan include Senior Director, Science and Technology Evaluation for Calvert Research, Senior Scientist in Clinical Development at Cato Research, and Director Pharmacology at Insmed Pharmaceuticals. Dr. Nolan started his career at Eastern Virginia Medical School where he had a joint appointment in Biochemistry and Internal Medicine and conducted basic and clinical research at the Strelitz Diabetes Research Center. He received a PhD in Pharmacology and Biochemistry from Melbourne University and completed Postdoctorate fellowships at the National Institute of Environmental Health Sciences and at Burroughs Wellcome.
Follow Roger Nolan:
About BioKier: BioKier is an early-stage pharmaceutical company that develops drugs for diabetes and related disorders.
Roger Nolan
Co-Founder, President and COO of BioKier
Roger Nolan is responsible for the development of BioKier’s drug candidates for type 2 diabetes, including capital-raising, preclinical, clinical and regulatory strategy, and management of consultant and strategic partner interactions. Dr. Nolan is experienced in management of preclinical and clinical drug development programs, regulatory strategy and interactions, evaluation of new technologies for in-licensing, and outsourcing to specialist service providers. His specific areas of expertise are in diabetes, oncology and cardiovascular indications. Previous positions held by Dr. Nolan include Senior Director, Science and Technology Evaluation for Calvert Research, Senior Scientist in Clinical Development at Cato Research, and Director Pharmacology at Insmed Pharmaceuticals. Dr. Nolan started his career at Eastern Virginia Medical School where he had a joint appointment in Biochemistry and Internal Medicine and conducted basic and clinical research at the Strelitz Diabetes Research Center. He received a PhD in Pharmacology and Biochemistry from Melbourne University and completed Postdoctorate fellowships at the National Institute of Environmental Health Sciences and at Burroughs Wellcome.
Follow Roger Nolan:
About BioKier: BioKier is an early-stage pharmaceutical company that develops drugs for diabetes and related disorders.